Muscle loss is a serious but often overlooked problem in people with advanced liver disease.
Many patients with end-stage liver disease gradually lose muscle mass and strength, making it harder to carry out daily activities, maintain independence, and recover from illness.
This condition, known as sarcopenia, affects about one in three people with severe liver disease and is associated with a much higher risk of falls, infections, hospitalization, and death.
Despite its major impact on health, doctors currently have very few options for treating muscle loss in these patients. Most treatments focus on nutrition and exercise, and there are no approved medications specifically designed to prevent or reverse sarcopenia in people with liver disease.
Now, a new study led by researchers at the University of Birmingham offers fresh insights into why muscle loss occurs and why some patients may respond differently to treatment.
The findings, published in the Journal of Cachexia, Sarcopenia and Muscle, suggest that different types of liver disease cause muscle loss through different biological pathways. This discovery could help pave the way for more personalized treatments in the future.
The researchers examined muscle tissue taken directly from people with end-stage liver disease and compared it with muscle tissue from healthy individuals. To understand what was happening inside the muscle cells, they used a powerful research technique called transcriptomics.
This method allows scientists to see which genes are active and which are inactive, providing a detailed picture of the biological processes occurring within tissues.
The analysis revealed more than 600 genes that behaved differently in patients with liver disease. Many of these genes were involved in important processes such as energy production, protein breakdown, inflammation, and cellular aging. These are all biological activities that can influence muscle health and growth.
However, one of the most important discoveries came when researchers separated patients according to the cause of their liver disease. Patients with alcohol-related liver disease, metabolic liver disease, and immune-related liver disease each showed unique patterns of gene activity in their muscles.
This finding suggests that muscle loss associated with liver disease is not one single condition. Instead, it appears to be a collection of related disorders, each driven by different biological mechanisms depending on the underlying liver disease.
Professor Simon Jones, the senior author of the study, explained that these findings challenge the traditional one-size-fits-all approach to treating sarcopenia. If different diseases cause muscle loss through different pathways, treatments may need to be tailored to individual patients rather than applied universally.
To better understand what might be causing these muscle changes, the team also analyzed blood samples from patients. They measured 60 different proteins, including proteins involved in inflammation, tissue repair, and growth regulation.
The researchers then exposed human muscle cells in the laboratory to blood plasma collected from patients with liver disease. Remarkably, the plasma caused changes in the cells that closely matched the changes observed in patient muscle tissue. The muscle cells became more prone to breaking down proteins and showed signs of impaired growth.
Three proteins stood out as particularly important. These were IL-1α, GDF-15, and HGF. The researchers believe these proteins may play major roles in driving muscle wasting.
GDF-15 was elevated in all forms of liver disease examined in the study, suggesting it may be a common factor contributing to muscle loss.
In contrast, IL-1α was mainly elevated in patients with immune-related liver disease, while HGF was more strongly associated with metabolic and alcohol-related liver disease. These differences further support the idea that distinct biological pathways are involved.
When researchers treated healthy muscle cells with these proteins at levels similar to those found in patients, the cells became thinner and showed disruptions in their energy production systems. These are classic signs of muscle wasting and helped confirm the proteins’ potential role in the disease process.
One particularly encouraging aspect of the research is that some of these proteins are already being targeted by medications used for other diseases. This raises the possibility that existing drugs could potentially be repurposed to treat muscle loss in liver disease patients.
The study represents an important advance in understanding sarcopenia. One major strength is that researchers analyzed actual patient muscle tissue rather than relying solely on animal models or laboratory experiments.
However, further studies will be needed to determine whether targeting these proteins can successfully improve muscle health in patients.
Overall, the findings suggest that personalized treatment approaches based on the type of liver disease may offer a more effective way to combat muscle loss and improve quality of life for people living with advanced liver disease.
If you care about liver health, please read studies that refined fiber is link to liver cancer, and the best and worst foods for liver health.
For more health information, please see recent studies about how to boost your liver naturally, and simple ways to detox your liver.
